Use of Rituximab in Autoimmune Hemolytic Anemia Associated with Non-Hodgkin Lymphomas

The association between non-Hodgkin lymphomas and autoimmune disorders is a well-known event. Also autoimmune hemolytic anemia (AHA), although much more frequent in patients with chronic lymphocytic leukemia (CLL), has been described in this group of patients. In recent years, among the more tradi...

Full description

Saved in:
Bibliographic Details
Main Authors: Claudio Fozza, Maurizio Longinotti
Format: Article
Language:English
Published: Wiley 2011-01-01
Series:Advances in Hematology
Online Access:http://dx.doi.org/10.1155/2011/960137
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832561304819204096
author Claudio Fozza
Maurizio Longinotti
author_facet Claudio Fozza
Maurizio Longinotti
author_sort Claudio Fozza
collection DOAJ
description The association between non-Hodgkin lymphomas and autoimmune disorders is a well-known event. Also autoimmune hemolytic anemia (AHA), although much more frequent in patients with chronic lymphocytic leukemia (CLL), has been described in this group of patients. In recent years, among the more traditional therapeutic options, rituximab, an anti-CD20 monoclonal antibody, has shown interesting results in the treatment of primary AHA. Although this drug has been frequently used for AHA in patients with CLL, much less data are available on its use in NHL patients. However, considering that the main pathogenetic mechanism of AHA in course of lymphoproliferative disorders seems to be an antibody production directly or indirectly mediated by the neoplastic clone, this monoclonal antibody represents an ideal therapeutic approach. In this paper we will briefly describe some biological and clinical features of NHL-patients with AHA. We will then analyze some studies focusing on rituximab in primary AHA, finally reviewing the available literature on the use of this drug in NHL related AHA.
format Article
id doaj-art-9ef33d9d02b140a99bb0020708808644
institution Kabale University
issn 1687-9104
1687-9112
language English
publishDate 2011-01-01
publisher Wiley
record_format Article
series Advances in Hematology
spelling doaj-art-9ef33d9d02b140a99bb00207088086442025-02-03T01:25:23ZengWileyAdvances in Hematology1687-91041687-91122011-01-01201110.1155/2011/960137960137Use of Rituximab in Autoimmune Hemolytic Anemia Associated with Non-Hodgkin LymphomasClaudio Fozza0Maurizio Longinotti1Institute of Hematology, University of Sassari, Viale San Pietro 12, 07100 Sassari, ItalyInstitute of Hematology, University of Sassari, Viale San Pietro 12, 07100 Sassari, ItalyThe association between non-Hodgkin lymphomas and autoimmune disorders is a well-known event. Also autoimmune hemolytic anemia (AHA), although much more frequent in patients with chronic lymphocytic leukemia (CLL), has been described in this group of patients. In recent years, among the more traditional therapeutic options, rituximab, an anti-CD20 monoclonal antibody, has shown interesting results in the treatment of primary AHA. Although this drug has been frequently used for AHA in patients with CLL, much less data are available on its use in NHL patients. However, considering that the main pathogenetic mechanism of AHA in course of lymphoproliferative disorders seems to be an antibody production directly or indirectly mediated by the neoplastic clone, this monoclonal antibody represents an ideal therapeutic approach. In this paper we will briefly describe some biological and clinical features of NHL-patients with AHA. We will then analyze some studies focusing on rituximab in primary AHA, finally reviewing the available literature on the use of this drug in NHL related AHA.http://dx.doi.org/10.1155/2011/960137
spellingShingle Claudio Fozza
Maurizio Longinotti
Use of Rituximab in Autoimmune Hemolytic Anemia Associated with Non-Hodgkin Lymphomas
Advances in Hematology
title Use of Rituximab in Autoimmune Hemolytic Anemia Associated with Non-Hodgkin Lymphomas
title_full Use of Rituximab in Autoimmune Hemolytic Anemia Associated with Non-Hodgkin Lymphomas
title_fullStr Use of Rituximab in Autoimmune Hemolytic Anemia Associated with Non-Hodgkin Lymphomas
title_full_unstemmed Use of Rituximab in Autoimmune Hemolytic Anemia Associated with Non-Hodgkin Lymphomas
title_short Use of Rituximab in Autoimmune Hemolytic Anemia Associated with Non-Hodgkin Lymphomas
title_sort use of rituximab in autoimmune hemolytic anemia associated with non hodgkin lymphomas
url http://dx.doi.org/10.1155/2011/960137
work_keys_str_mv AT claudiofozza useofrituximabinautoimmunehemolyticanemiaassociatedwithnonhodgkinlymphomas
AT mauriziolonginotti useofrituximabinautoimmunehemolyticanemiaassociatedwithnonhodgkinlymphomas